An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?
(2019) In Nature Biotechnology 37(1). p.21-22- Abstract
- A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8a6e56b2-a28d-4447-84ed-77b74bf8282c
- author
- Minssen, Timo LU ; Kesselheim, Aaron and Darrow, Jonathan
- publishing date
- 2019-01-03
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Medical law, Medicinsk rätt
- in
- Nature Biotechnology
- volume
- 37
- issue
- 1
- pages
- 2 pages
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:85059503599
- ISSN
- 1087-0156
- DOI
- 10.1038/nbt.4324
- language
- English
- LU publication?
- no
- id
- 8a6e56b2-a28d-4447-84ed-77b74bf8282c
- date added to LUP
- 2020-12-16 14:14:54
- date last changed
- 2022-04-26 22:36:56
@article{8a6e56b2-a28d-4447-84ed-77b74bf8282c, abstract = {{A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.}}, author = {{Minssen, Timo and Kesselheim, Aaron and Darrow, Jonathan}}, issn = {{1087-0156}}, keywords = {{Medical law; Medicinsk rätt}}, language = {{eng}}, month = {{01}}, number = {{1}}, pages = {{21--22}}, publisher = {{Nature Publishing Group}}, series = {{Nature Biotechnology}}, title = {{An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?}}, url = {{http://dx.doi.org/10.1038/nbt.4324}}, doi = {{10.1038/nbt.4324}}, volume = {{37}}, year = {{2019}}, }